Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option

Q: How much expense ratio is charged by Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?

The expense ratio for Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option, or any other mutual fund, is the yearly fee you pay for managing your investments. As of 21 Jan 2026, the expense ratio charged by Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option is typically around 1.12 %. This fee covers fund management, administrative, and other operational costs. It is relatively low compared to actively managed funds, reflecting its direct growth option.

Q: What is the AUM of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?

As of 21 Jan 2026, the Assets Under Management (AUM) of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option is approximately ₹8264.7099 crore. The AUM can fluctuate based on market conditions and investor activity. It indicates the total value of assets managed by the fund.

Q: What is the NAV of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?

The Net Asset Value (NAV) of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option is updated daily and reflects the per-unit value of the fund's assets. As of 21 Jan 2026 , the NAV is around undefined per unit, but this value might change based on market performance and fund holdings.

Q: What is the PE and PB ratio of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?

The PE ratio for Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option is 41.68 and the PB ratio is 7.85. The PE ratio is calculated by dividing the market price by the earnings per share, whereas the PB ratio is calculated by dividing the stock price by the book value per share.

Q: What is the exit load of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?

The exit load for Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option is 1% if units are redeemed within 30 days from the date of investment. After this period, no exit load is applicable. This fee is charged to discourage short-term trading and ensure long-term investment.

Equity

NAV

₹ 544.74

CAGR (3 Years)

22.20%

AUM (Cr)

₹ 8,264.71

Risk

Very High Risk

About Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option

The primary investment objective of the Scheme is to generate consistent returns by investing in equity / equity related or fixed income securities of Pharma and other associated companies

Breakdown of this Fund

Debt Others

3.16%

Healthcare

41.28%

Pharmaceuticals

106.93%

Retail

7.01%

Market Capitalization

Expense Ratio, Exit Load and Tax

Expense Ratio

1.12

Exit Load

1% if redeemed or switched out on or before completion of 1 Months from the date...

Stamp Duty

0.005% (from July 1st, 2020)

Tax Implication

Returns are taxed at 20%, if you redeem before one year. After 1 year, you are required to pay LTCG tax of 12.5% on returns of Rs 1.25 lakh+ in a financial year.